TCR's genetically linked to CD28 and CD3e do not mispair with endogous TCR chains and mediate enhanced T cell persistance and anti-melanoma activity

C.C.F.M. Govers, Z. Sebestyen, J. Roszik, M. van Brakel, C. Berrevoets, A. Szoor, K. Panoutsopoulou, M. Broertjes, T. Van, G. Vereb, J. Szollosi, R. Debets

Research output: Contribution to journalArticleAcademicpeer-review

20 Citations (Scopus)

Abstract

Adoptive transfer of T cells that are gene engineered to express a defined TCR represents a feasible and promising therapy for patients with tumors. However, TCR gene therapy is hindered by the transient presence and effectiveness of transferred T cells, which are anticipated to be improved by adequate T cell costimulation. In this article, we report the identification and characterization of a novel two-chain TCR linked to CD28 and CD3e (i.e., TCR:28e). This modified TCR demonstrates enhanced binding of peptide–MHC and mediates enhanced T cell function following stimulation with peptide compared with wild-type TCR. Surface expression of TCR:28e depends on the transmembrane domain of CD28, whereas T cell functions depend on the intracellular domains of both CD28 and CD3e, with IL-2 production showing dependency on CD28:LCK binding. TCR:28e, but not wild-type TCR, induces detectable immune synapses in primary human T cells, and such immune synapses show significantly enhanced accumulation of TCR transgenes and markers of early TCR signaling, such as phosphorylated LCK and ERK. Importantly, TCR:28e does not show signs of off-target recognition, as evidenced by lack of TCR mispairing, as well as preserved specificity. Notably, when testing TCR:28e in immune-competent mice, we observed a drastic increase in T cell survival, which was accompanied by regression of large melanomas with limited recurrence. Our data argue that TCR transgenes that contain CD28, and, thereby, may provide T cell costimulation in an immune-suppressive environment, represent candidate receptors to treat patients with tumors.
Original languageEnglish
Pages (from-to)5315-5326
JournalThe Journal of Immunology
Volume193
Issue number10
DOIs
Publication statusPublished - 2014

Keywords

  • chimeric-antigen-receptor
  • gene-transfer
  • metastatic melanoma
  • cancer regression
  • lymphocytes
  • therapy
  • alpha
  • activation
  • toxicity
  • survival

Fingerprint Dive into the research topics of 'TCR's genetically linked to CD28 and CD3e do not mispair with endogous TCR chains and mediate enhanced T cell persistance and anti-melanoma activity'. Together they form a unique fingerprint.

  • Cite this

    Govers, C. C. F. M., Sebestyen, Z., Roszik, J., van Brakel, M., Berrevoets, C., Szoor, A., Panoutsopoulou, K., Broertjes, M., Van, T., Vereb, G., Szollosi, J., & Debets, R. (2014). TCR's genetically linked to CD28 and CD3e do not mispair with endogous TCR chains and mediate enhanced T cell persistance and anti-melanoma activity. The Journal of Immunology, 193(10), 5315-5326. https://doi.org/10.4049/jimmunol.1302074